

**FOR IMMEDIATE RELEASE**

**Powder Pharmaceuticals made submission to US FDA  
for approval of Hong Kong manufacturing facility**

**Hong Kong, October 30, 2012** – Lee’s Pharmaceutical Holdings Limited (“the Group”) (Main Board Stock Code: 0950; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that Powder Pharmaceuticals, Incorporated (“PPI”), an associated company of the Group, has submitted the amendment with the U.S. FDA for approval of the production of Zingo™ in the new Hong Kong manufacturing facility on 29<sup>th</sup> October 2012.

Zingo™ is an FDA approved, needle-less, painless, fast, Lidocaine powder injection system that provides local analgesia for children age 3 and over as well as adults prior to IV/cannula placements. In January 2009, PPI acquired the entire assets of Zingo™ franchise and moved the production facility to Hong Kong. PPI has since worked diligently to establish the new site according to FDA requirements. The submission will initiate the process of certification for the new manufacturing facility in Hong Kong by US FDA. The successful completion of this process will ensue the relaunch of Zingo™ in US market.

“This is a significant milestone achieved by PPI and paved the way for relaunch of the Zingo™ in US,” commented by Dr. Benjamin Li, CEO of PPI. “I would like to congratulate the PPI team for their hard work and dedication. If it is approved, PPI will be the first company to produce pharmaceutical product for the US market in Hong Kong.”

**About Zingo™**

Zingo™ is the first needleless, painless powder injection system to be approved for analgesia at an IV/cannula access site. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain free needle access procedure. Zingo™ is approved for use in children over 3 years of age and adults. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo™ versus a placebo system.

### **About PPI**

Powder Pharmaceuticals Inc. is a privately held company based in Hong Kong, for development of products that utilize a proprietary needleless, painless, powder delivery technology. Powder Pharmaceuticals intends to supply Zingo™ globally through international business partners.

### **About Lee's**

Lee's Pharmaceutical Holdings Limited ("Lee's") is a research-based Hong Kong biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with 20 international companies and currently has 13 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. For further information about Lee's Pharmaceutical: Website: [www.leespharm.com](http://www.leespharm.com)

### **Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*